Instead, the fact that PD-L1-induced activation of STAT3 and STAT1 requires, as a prerequisite, that PD-L1 will be N-linked glycosylated, provides novel perspectives to PD-L1-directed therapy in breast cancer patients. This evidence concerns the gene STAT1 and breast cancer.